• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. Eur Urol 2020;78:907-15: Linking FGFR3 Mutation Status and Luminal Papillary Subtype to Response to Cisplatin-based Chemotherapy in Bladder Cancer.

作者信息

Roumiguie Mathieu, Contreras-Sanz Alberto, Black Peter C

机构信息

Department of Urology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.

Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.

出版信息

Eur Urol. 2021 Jun;79(6):e182-e183. doi: 10.1016/j.eururo.2021.03.028. Epub 2021 Apr 8.

DOI:10.1016/j.eururo.2021.03.028
PMID:33838962
Abstract
摘要

相似文献

1
Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. Eur Urol 2020;78:907-15: Linking FGFR3 Mutation Status and Luminal Papillary Subtype to Response to Cisplatin-based Chemotherapy in Bladder Cancer.回复：明·阮·蒂奥、何塞·毛里西奥·莫塔、卡丽莎·A·怀廷等。成纤维细胞生长因子受体3改变状态与局部晚期和转移性尿路上皮癌对铂类化疗的不同敏感性相关。《欧洲泌尿外科杂志》2020年；78卷：907 - 15页：将FGFR3突变状态和管腔乳头状亚型与膀胱癌对顺铂化疗的反应联系起来。
Eur Urol. 2021 Jun;79(6):e182-e183. doi: 10.1016/j.eururo.2021.03.028. Epub 2021 Apr 8.
2
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.成纤维细胞生长因子受体 3 改变状态与局部晚期和转移性尿路上皮癌对铂类化疗的敏感性差异相关。
Eur Urol. 2020 Dec;78(6):907-915. doi: 10.1016/j.eururo.2020.07.018. Epub 2020 Aug 1.
3
FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.FGFR3过表达是接受辅助化疗的肌层浸润性膀胱癌不良预后的预测指标。
Urol Oncol. 2014 Jan;32(1):49.e23-31. doi: 10.1016/j.urolonc.2013.07.015.
4
Re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019;76:9-13.回复：施明君、孟祥宇、菲利普·拉米等人。载脂蛋白B编辑酶催化多肽样蛋白介导的诱变可能是膀胱癌中FGFR3 S249C突变过度表达的原因。《欧洲泌尿外科杂志》2019年；76卷：第9 - 13页。
Eur Urol. 2020 Jan;77(1):e24-e25. doi: 10.1016/j.eururo.2019.08.018. Epub 2019 Aug 30.
5
Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8.回复：何塞·路易斯·佩雷斯 - 格拉西亚、约安·洛里奥、乔纳森·E·罗森伯格等。阿替利珠单抗用于铂类治疗的局部晚期或转移性尿路上皮癌：根据既往治疗方案数量的疗效。《欧洲泌尿外科杂志》2018年；73卷：462 - 468页。
Eur Urol. 2018 Jul;74(1):e12-e13. doi: 10.1016/j.eururo.2018.03.034. Epub 2018 Apr 12.
6
Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma" [Eur Urol 2020;78:907-15].
Eur Urol. 2021 May;79(5):e158-e159. doi: 10.1016/j.eururo.2021.01.031. Epub 2021 Feb 9.
7
Fibroblast growth factor receptor () gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder.成纤维细胞生长因子受体（）基因：膀胱癌中的发病机制和治疗意义。
J Clin Pathol. 2021 Aug;74(8):491-495. doi: 10.1136/jclinpath-2020-207115. Epub 2021 Mar 17.
8
Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.膀胱乳头状尿路上皮癌的分级异质性分析：CDKN2A缺失在FGFR3通路中早期作用的支持证据
Histopathology. 2017 Jan;70(2):281-289. doi: 10.1111/his.13063. Epub 2016 Oct 28.
9
Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.检查点抑制剂：治疗尿路上皮膀胱癌的新模式。
Med Oncol. 2017 Sep 1;34(10):170. doi: 10.1007/s12032-017-1029-8.
10
Reply to Francesco Massari and Vincenzo Di Nunno's Letter to the Editor re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8.对弗朗切斯科·马萨里和文森佐·迪农诺致编辑的信的回复，信的主题为：何塞·路易斯·佩雷斯 - 格拉西亚、约安·洛里奥、乔纳森·E·罗森伯格等人。阿替利珠单抗治疗铂类治疗后的局部晚期或转移性尿路上皮癌：根据既往治疗方案数量的疗效。《欧洲泌尿外科杂志》2018年；73卷：462 - 468页。
Eur Urol. 2018 Jul;74(1):e14. doi: 10.1016/j.eururo.2018.03.035. Epub 2018 Apr 13.